Innova Biosciences has been awarded EUR455,000 (GBP408,000) of a EUR3m European grant to develop a high-throughput plasma screening platform for the discovery of biomarkers of early-stage cancer.
Innova will be working to develop immunodiagnostics reagents with the Proactive consortium along with Olink, Copenhagen University, Fujirebio Diagnostics AB, Uppsala University and Integromics SL.
Innova Biosciences has a range of Lightning-Link bioconjugation products, which provide a simple method for joining biomolecules, a process carried out in thousands of research laboratories worldwide.
